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AbsTrACT
background chemsex, the use of select psychoactive 
drugs to enhance sexual experience, typically among men 
who have sex with men (MsM), is associated with sexual 
behaviours with higher sTi risk. Understanding patterns 
of chemsex among MsM as well as the characteristics 
and sexual health service engagement of chemsex 
participants is important for developing interventions.
Methods Between 5/2016 to 5/2017, 3933 MsM 
completed an online survey, recruited in sexual health 
clinics (shcs) in england (n=421) and via four social 
networking/dating apps (n=3512). We described 
patterns of chemsex in the past year and used 
multivariable logistic regression to investigate differences 
in demographics and sexual behaviours by chemsex 
history. We described history of shc attendance and 
sTi test in the past year among app- recruited chemsex 
participants.
results chemsex in the past year was reported by 
10% of respondents; 19% of shc- recruited and 9% of 
app- recruited. among chemsex participants, 74% had 
used ≥2 chemsex drugs. in the multivariable model, 
MsM engaging in chemsex had a raised odds of being 
hiV- positive (adjusted Or (aOr): 3.6; 95% ci 2.1 to 6.1), 
aged 30–44 (aOr 1.5 vs <30 years; 95% ci 1.0 to 2.1), 
being born outside the UK and having engaged in higher 
risk sexual behaviours in the past 3 months. chemsex 
participants also had higher odds of condomless anal 
sex with partners of different or unknown hiV status, but 
only among hiV- negative/untested. in the past year, 66% 
of app- recruited chemsex participants had attended a 
shc and 81% had had an sTi test.
Conclusion One in 10 MsM recruited through 
community and clinical settings across england had 
engaged in chemsex in the past year. Those that did 
appear to be at greater sTi risk but engaged more 
actively with sexual health services. This highlights the 
need and opportunity for chemsex- related services in 
shcs and robust referral pathways to drug treatment 
services.
InTroduCTIon
Chemsex refers to the use of specific recreational 
drugs before and/or during sexual activity to 
enhance the sexual experience of gay, bisexual 
and other men who have sex with men (MSM).1 
The drugs, typically mephedrone, gamma- 
hydroxybutyrate/gamma- butyrolactone (GHB/
GBL), crystal methamphetamine and to a lesser 
extent ketamine,1 2 encourage disinhibition and 
enhance libido and stamina.3 4
Chemsex is a recognised public health concern. 
As well as risks of drug addiction and harms arising 
from injecting drug use, there is increased potential 
for transmission of sexually transmitted infections 
(STIs) and HIV as well as other bloodborne viruses 
such as hepatitis C.4 This is due to the enhanced 
drive and ability to have multiple sex partners over 
a short time, often without condoms and with addi-
tional higher risk sexual practices (e.g., fisting).1 2 4 
These health risks are likely facilitated by the use 
of social networking/dating apps (simplified here to 
‘apps’) to find sex partners.2
However, chemsex does not always mean harm 
to an individual’s sexual health. Controlled drug 
use and risk management are possible.5 Risk of 
HIV/STI transmission for instance can be miti-
gated by condom use during chemsex sessions and 
timely access to STI screens or sexual health advice. 
Understanding the prevalence of chemsex and the 
characteristics, sexual behaviours and healthcare 
access of those who engage in it is important for 
understanding the health risks associated with 
chemsex and for designing interventions to address 
them.
Prior to this work, research into chemsex preva-
lence among MSM in England, and their character-
istics, had been undertaken in mostly clinic- based 
studies or studies with few sites.1 4 6 One study 
looked into sexual health service engagement 
among community- representative chemsex partici-
pants in London, England, and found that 70% of 
HIV- negative respondents had attended a sexual 
health clinic (SHC) in the last year.6 A survey across 
the UK (excluding England) and Ireland found that 
64% of chemsex- participating MSM had had an 
HIV test in the past year.7 Additionally, a survey 
distributed to SHCs in the UK found that half of 
healthcare workers had a chemsex consultation at 
least monthly.8
The aim of this study was to better understand 
the degree to which MSM in England engage in 
chemsex and the associated demographic and 
behavioural factors. We also determined the 
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proportion of MSM engaging in chemsex who attended SHCs 
or had an STI test.
METhods
study design
Data were collected for the Reducing Inequalities and Improving 
Sexual Health study, undertaken 2016–2017 for the National 
Institute for Health Research Health Protection Research Unit 
for Blood Borne and Sexually Transmitted Infections. This cross- 
sectional study administered an online survey to MSM in clinical 
settings and via apps. Comprehensive methodology details have 
previously been published9 and are summarised below.
study setting
The clinical setting comprised of 16 SHCs across England with 
particularly high proportions of MSM attendees, in London, 
Birmingham, Manchester and Leeds. Between May and 
September 2016, staff handed out paper invitations to SHC 
attendees, on which the survey weblink was printed. Respon-
dents could complete the survey in the clinic using the study 
tablet or at any time on their own internet- enabled device (eg, 
smart phone). The questionnaire collected information on 
demographics, healthcare- seeking behaviour, sexual behaviour 
and drug use.
Between March and May 2017, the same survey was promoted 
via three apps (Scruff, Gaydar, Grindr) which displayed a pop- up 
message with a survey link. The link was also posted on the home 
page for Sigma Research, one of the research centres affiliated 
with this study (http:// sigmaresearch. org. uk/). No incentives 
were offered for either recruitment method.
Eligibility criteria
Screening questions at the beginning of the questionnaire filtered 
to eligible respondents: men aged at least 16, who reported sex 
with a man in the last 12 months, and who consented to partic-
ipate in the survey. In the app version of the survey, an addi-
tional screening question asked if respondents had previously 
completed the survey in clinic, and these men were excluded to 
prevent duplication.
Analysis
Description of study population
We first described the study population in terms of overall 
numbers and distribution of demographic characteristics, strati-
fied by recruitment method.
History of chemsex in 12 months prior to survey
We described the proportion of all respondents who reported 
using a chemsex drug in the past 12 months, here defined as 
crystal methamphetamine, mephedrone, GHB/GBL or ketamine. 
We then described the proportions of respondents who had 
chemsex in the past 12 months, which we defined as having sex 
after taking any of the above drugs. For simplicity, we do not 
always explicitly refer to the 12 months in this paper. We strati-
fied results by HIV status.
Comparison of demographic factors and sexual behaviour by 
chemsex participation in past 12 months
To investigate factors associated with chemsex, we presented 
the distribution of demographic factors and sexual behaviours 
among MSM who did and did not report chemsex in the past 12 
months. Demographic factors were captured by the following 
categorical variables: age group, ethnic group, continent 
of birth, highest educational qualification, and HIV status. 
Ethnicity groupings were based on broad categories used by the 
UK’s Office for National Statistics (who use White, Black, Asian, 
Mixed, and Other).10 Sexual behaviour was captured by the 
following variables on sex with men in the past 3 months: binary 
variables for if they had a new male partner or had condomless 
anal sex (CAS) and categorical variables on number of partners 
and HIV serostatus of partners among those reporting CAS (all 
partners’ statuses known and all seroconcordant, all known and 
some serodiscordant, and at least one serostatus unknown).
We conducted a univariable logistic regression analysis 
to compare these characteristics by chemsex participation, 
reporting crude odds ratios (ORs) and global p values. To 
address the interplay between these factors, we then constructed 
a multivariable logistic regression model based on variables 
where p values from the univariable analysis were <0.05. We 
used a forward- building method introducing variables in order 
of highest to lowest measure of effect and maintained variables 
if their addition to the model resulted in an improvement of fit 
with a likelihood ratio test p<0.05. We checked for evidence 
of substantial confounding, demonstrated by change to an OR 
by >10% when adding a new variable; if the variable no longer 
had a significant association (at p<0.05) with the outcome of 
chemsex it was dropped. Once the variables in the multivari-
able model were decided, we checked for two- way effect modi-
fication due to HIV status. Only plausible interactions were 
checked, and interaction terms were maintained in the model if 
significant at p<0.05.
Finally, to check for clustering among individuals recruited 
in the same site, we added a random intercept (a categorical 
variable distinguishing between apps and specific SHCs) and 
conducted a likelihood ratio test to determine if this improved 
the model (if p<0.05).
History of SHC attendance by chemsex use among respondents 
recruited via apps
We investigated the proportion of respondents who had attended 
a SHC or had an STI test in the 12 months prior to completing 
the survey, by history of chemsex. This analysis was restricted to 
men recruited via apps, as including SHC- recruited men would 
have overestimated SHC attendance.
Data were analysed using Stata (V.14.2). All percentages are 
presented with 95% CIs and are based on non- missing responses. 
Where appropriate, we report missingness of data.
rEsulTs
description of study population
The survey was completed by 3933 eligible MSM, of which 421 
were recruited in SHCs and 3512 via apps: 54% Grindr, 44% 
Gaydar, 2% Scruff and <1% the Sigma webpage (online supple-
mentary material figure 1).
The median respondent age was 43 years (IQR 31–53 years), 
90% identified as white ethnicity, 19% were non- UK born and 
52% were university educated. Clinic survey respondents were 
younger and were more likely to be university educated, born 
outside the UK, and of non- white ethnicity (p<0.001; detail in 
online supplementary material table 1). Overall, 14% (n=557) 
of respondents reported being diagnosed with HIV, although this 
was higher in the SHC- recruited group (23% vs 13%, p<0.001). 
In our sample, HIV- positive persons were slightly older (median 
age 47 vs 43) and more likely to be white than HIV- negative/
untested (94% vs 90%, p=0.002).
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Figure 1 Chemsex drugs used in the 12 months prior to completing 
RiiSH MSM survey (2016–2017) among (A) all respondents and (B) 
respondents reporting chemsex in the past 12 months, in total and 
by HIV status. Non- missing percentages to 0 decimal places and CIs 
presented. GBL, gamma- butyrolactone; GHB, gamma- hydroxybutyrate; 
MSM, men who have sex with men.
history of chemsex in 12 months prior to survey
Chemsex status was documented for 3922 respondents (99.7% 
completeness). As figure 1 shows, 11.7% reported using at least 
one chemsex drug in the past 12 months. Among them (n=460), 
87.6% used these drugs for chemsex. This equated to 10.1% of 
all respondents.
Chemsex varied by recruitment method: 19.2% of SHC- 
recruited respondents reported chemsex in the past 12 months 
compared with 9.0% of app- recruited individuals. Chemsex 
participation was also distinctly higher among HIV- positive 
(23.9%) than HIV- negative/unknown MSM (7.8%; figure 1A).
Among the 397 MSM reporting chemsex (figure 1B), 74.1% 
reported using two or more chemsex drugs, whereas 25.9% used 
only one. This was slightly higher in HIV- positive respondents 
(n=133): 82.0% and 18.1% respectively. Use of GHB/GBL 
was most commonly reported (68.9% of chemsex participants) 
while ketamine was least frequently reported (32.8%). Specific 
drug preferences differed little by HIV status, except that crystal 
methamphetamine use was higher in HIV- positive MSM.
Comparison of demographic factors and sexual behaviour by 
chemsex participation in past 12 months
Univariable analysis
Our univariable analysis found associations between chemsex 
and all investigated variables (table 1). Compared with MSM who 
did not report chemsex, a higher proportion of chemsex partic-
ipants were aged 30–44 (40.3% vs 30.9%), university educated 
(59.5% vs 51.3%), and HIV- positive (33.8% vs 12.0%). While 
approximately 90% of both groups identified as white ethnicity, 
more chemsex- reporting MSM identified specifically as ‘white 
other’ (17.6% vs 9.0%) and were born outside the UK.
In terms of sexual behaviour, a higher proportion of chemsex- 
reporting MSM reported each of the following in the past 3 
months: >10 male sexual partners (29.4% vs 10.5%), a new 
male partner (82.9% vs 67.0%), and CAS (75.9% vs 48.8%). 
Among those who reported CAS, a higher proportion of 
chemsex participants (n=296) reported CAS with at least one 
partner with a different (28.3% vs 19.7%) or unknown HIV 
status (23.6% vs 20.3%).
Multivariable logistic regression
In the multivariable model, the odds of chemsex were raised 
in those aged 30–44, born in mainland Europe, Australasia or 
Africa, and HIV- positive (figure 2). Ethnic group and university 
education were no longer associated with chemsex, as these were 
confounded by birth continent (detail in online supplementary 
material table 2).
MSM engaging in chemsex had a 2.1 times higher adjusted 
odds of >10 sexual partners in the past 3 months compared with 
MSM who did not report chemsex (95% CI 1.6 to 2.9), and a 
1.7 times higher adjusted odds of a new male sexual partner in 
the last 3 months (95% CI 1.2 to 2.4).
Due to collinearity, the final multivariable model used a 
composite variable combining history of CAS and HIV status of 
CAS partner(s) in the past 3 months. MSM engaging in chemsex 
had a higher odds of reporting CAS, particularly with a serocon-
cordant partner, however the effect was modified by HIV status. 
When comparing HIV- negative/untested men who did and did 
not engage in chemsex, those who reported chemsex had a 2.0 
times higher odds of engaging in CAS only with other known 
HIV- negative partners and even higher odds of CAS with a HIV- 
positive partner (adjusted OR (aOR): 4.0 95% CI: 2.5 to 6.3) or 
partner of unknown HIV status (aOR: 3.0, 95% CI: 1.9 to 4.8). 
Among HIV- positive MSM, those engaging in chemsex had a 4.4 
times higher odds of engaging in CAS with only HIV- positive 
partners (95% CI 2.4 to 8.2), but there was no evidence of a 
higher odds of sex with partner(s) of unknown status or who 
were HIV- negative. The corresponding percentages for these 
interacting variables are in online supplementary material table 
3.
We did not add a random effect for specific recruitment site, 
as the mixed effects model did not improve the fit (p=1.00), 
indicating homogeneity of outcome between clinics.
sexual health service use in the past 12 months among app-
recruited respondents
SHC attendance and STI testing history were reported by 3232 
(92.1%) and 3109 (88.5%) of app- recruited respondents, respec-
tively. In the past 12 months, 37.4% had attended a SHC and 
56.1% had had an STI test (figure 3). These percentages were 
higher among chemsex participants (65.5% attended a SHC and 
81.0% had an STI test) and even higher among HIV- positive 
chemsex participants (81.4% and 87.6%, respectively).
dIsCussIon
In this large multicentre study of MSM recruited from apps 
and SHCs across England, 1 in 10 men reported engaging in 
chemsex in the past 12 months. Chemsex was more common 
among specific subgroups: one in four HIV- positive MSM and 
one in five MSM recruited via SHCs.
We confirmed that use of crystal meth, mephedrone, GHB/
GBL, and ketamine is mostly sexualised among MSM. Further-
more, three of four chemsex participants used multiple chemsex 
drugs, although it is unknown if they were used in the same 
session.
MSM engaging in chemsex were more likely to be clustered in 
the 30–44 age group, be born in Australasia, mainland Europe 
or Africa, have multiple or new sexual partners, and engage in 
CAS. Chemsex participants were more likely to report part-
ners with a different or unknown HIV status, but only among 
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Table 1 Demographic characteristics and sexual behaviour in 3 months prior to completing RiiSH MSM survey (2016–2017), by chemsex 
participation in the past 12 months
non- missing percentage univariable logistic regression
no chemsex 
last 12 months 
(n=3525) (%)
Chemsex in last 12 
months (n=397) (%) Total (n=3933) (%) or CI Global p value
Recruitment method
  App survey 90.4 79.8 89.3 – –
  Clinic survey 9.6 20.2 10.7 2.39 1.82 to 3.13 <0.001
Age group
  16–29 21.1 17.6 20.7 – –
  30–44 30.9 40.3 31.9 1.57 1.16 to 2.10 <0.001
  45–59 36.0 36.0 36.0 1.20 0.88 to 1.62
  60+ 12.0 6.0 11.4 1.20 0.37 to 0.98
Ethnic group*
  White British/Irish 81.3 71.8 80.2 – –
  White other 9.0 17.6 10.0 2.20 1.65 to 2.94 0.049
  Black 2.1 2.5 2.2 1.36 0.69 to 2.66
  Asian 4.0 4.3 4.1 1.23 0.73 to 2.07
  Mixed ethnicity 2.5 3.3 2.6 1.52 0.83 to 2.26
  Other 1.1 0.5 1.0 0.55 0.13 to 2.27
Continent of birth*
  UK 83.0 72.3 81.9 –
  Africa 2.0 3.6 2.2 2.00 1.11 to 3.60 <0.001
  Asia 3.4 3.1 3.3 1.04 0.56 to 1.91
  Australasia 1.0 2.8 1.2 3.19 1.60 to 6.36
  Mainland Europe 7.9 14.5 8.6 2.11 1.54 to 2.87
  North America 1.2 1.5 1.3 1.42 0.59 to 3.36
  South America 1.4 2.3 1.5 1.87 0.90 to 3.84
Highest qualification received*
  Below degree 48.7 40.5 47.8 – –
  University degree or higher 51.3 59.5 52.2 1.40 1.13 to 1.73 0.002
HIV status*
  No known HIV diagnosis 88.0 66.2 85.8 – –
  HIV- positive 12.0 33.8 14.2 3.74 2.96 to 4.71 <0.001
No. male partners in past 3 months†
  None 11.2 4.4 10.6 – –
  1–5 64.9 45.3 62.9 1.78 1.05 to 3.02 <0.001
  6–10 13.3 20.9 14.1 4.00 2.29 to 6.98
  11+ 10.5 29.4 12.4 7.16 4.15 to 2.37
New male sexual partner in past 3 months†
  No 33.0 17.1 31.4 – –
  Yes 67.0 82.9 68.6 2.38 1.78 to 3.19 <0.001
CAS with man in past 3 months*
  No 51.2 24.1 48.4 – –
  Yes 48.8 75.9 51.6 3.30 2.59 to 4.2 <0.001
HIV status of CAS partners(s) in past 3 months among those reporting CAS (no chemsex n=1676, chemsex n=296)‡
  HIV status known: seroconcordant partner(s) 
only
60.0 48.1 58.1 – –
  HIV status known: at least one serodiscordant 
partner
19.7 28.3 21.1 1.79 1.30 to 2.47 0.001
  Unknown HIV serostatus in at least one 
partner
20.3 23.6 20.8 1.46 1.04 to 2.04
Total 100.0 100.0 100.0
Non- missing percentages presented.
*Variables have <2.5% missing data with no difference by chemsex participation.
†Variables have 9%–15% missing data with no difference by chemsex participation.
‡Variable has 17.9% missing data among persons reporting CAS: 12% and 18% of those who did and did not report chemsex.
CAS, condomless anal sex; MSM, men who have sex with men; RiiSH, Reducing Inequalities and Improving Sexual Health.
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Figure 2 Multivariable logistic regression results: demographic factors 
and sexual behaviours associated with chemsex in the 12 months prior 
to completing RiiSH MSM survey (2016–2017). Adjusted ORs and 95% 
CIs presented to two decimal places. *Effect modification: calculated 
ORs shown within HIV- positive and HIV- negative/untested subgroups; 
**P value for interaction shown. CAS, condomless anal sex; MSM, men 
who have sex with men; RiiSH, Reducing Inequalities and Improving 
Sexual Health.
Figure 3 Proportions of MSM reporting (A) a SHC attendance and 
(B) an STI test in the 12 months prior to completing the RiiSH MSM 
survey (2016–2017), by HIV status and history of chemsex of the past 
12 months. Non- missing percentages to 0 decimal places and 95% 
CIs presented. MSM, men who have sex with men; RiiSH, Reducing 
Inequalities and Improving Sexual Health; SHC, sexual health clinic.
the HIV- negative/untested. Chemsex was not associated with 
ethnicity or education, as these relationships were confounded 
by continent of birth: MSM originating from non- UK countries 
were more educated.
Finally, most MSM engaging in chemsex in the past 12 months 
had attended a SHC or had an STI test in the corresponding 
period. The higher healthcare engagement among HIV- positive 
MSM likely reflects HIV- related care.
This was a large study and the only one we are aware of to 
investigate chemsex among respondents recruited from both 
apps and SHCs in cities across England. It is also one of the 
first to ask community- recruited chemsex- reporting MSM in 
England about SHC use.
However, as this is a cross- sectional survey, we do not know if 
the SHC attendance took place before or after chemsex. We did 
not collect information on chemsex- related health problems, so 
cannot estimate the need for sexual health or drugs services in 
this population. Although pre- exposure prophylaxis (PrEP) for 
HIV was becoming available during our study,11 we did not ask 
about it, and this may have been a relevant factor influencing 
sexual behaviour and partner choice.
Our study findings are not necessarily generalisable to MSM 
across England. App users may be more engaged with tech-
nology, more sexually active and more health- aware than the 
general MSM population. However, there is evidence that MSM 
recruited online are more representative geographically of the 
general MSM population than those recruited in SHCs.12 Finally, 
we may have under- represented individuals born outside the UK, 
as the survey was only in English.
Our findings of 9% app- recruited MSM reporting chemsex 
are similar to prevalence estimates in some community- based 
studies: 9% among Brighton MSM13 and 8% among app- 
recruited MSM in the UK (excluding England) and Ireland,7 
although lower than the 21% among HIV- negative MSM in 
London.6 Additionally, our 19% chemsex estimate among SHC- 
recruited MSM falls within the range seen in other SHC- focused 
studies in England.1 4 However, the sampling methods, chemsex 
definitions, and look- back periods differ. Our study is also more 
representative of SHCs across England. Importantly, while these 
are two separate recruitment methods, these are not mutually 
exclusive populations: for example, some SHC- recruited persons 
will also be app users and vice versa.
Other works have also noted that chemsex- participating MSM 
in England are mostly in their 30s and 40s, white, highly educated 
and report greater sexual risk behaviours.4 6 However, this study 
has also explored how HIV status is associated with these behav-
iours and how ethnicity and education are confounded by birth 
continent. These analyses were enabled by our larger sample size.
Finally, the high engagement with SHCs among study respond-
ents, particularly those reporting chemsex, has been seen else-
where4 6 7 and is consistent with research demonstrating that 
chemsex- participating MSM are comfortable accessing SHCs14 
and chemsex- related consultations in SHCs are common.8 
However, we cannot know how much chemsex was addressed in 
the SHC visits reported by our study respondents.
Chemsex was not widespread among study respondents, 
but the associated sexual behaviours demonstrate the need for 
chemsex participants to engage with sexual health services. 
Fortunately, we did find SHC visits and STI testing to be higher 
in this group, indicating risk management through either proac-
tive check- ups and/or responses to symptoms/known exposures. 
This also corroborates with our finding that chemsex was higher 
among those recruited in SHCs compared with apps.
The generally high SHC use presents a viable opportunity to 
provide chemsex- related sexual health services, particularly in 
venues providing HIV care. Considering findings from other 
research that only a third of SHCs have chemsex care- pathways 
in place,8 there have likely been missed opportunities to address 
wider health needs such as mental health and other drug- related 
harms.
Healthcare professionals should harness visits to SHCs to 
identify and support chemsex- related needs, through better inte-
gration or connectivity between drug/alcohol and sexual health 
services. While integration may be unrealistic in smaller clinics or 
challenging due to differences in commissioning,3 basic training 
of SHC staff in drugs and alcohol and the setup of referral 
systems and effective signposting is feasible and useful. These 
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synergies should not be limited to SHCs: the higher proportion 
of individuals that had an STI screen than had visited a SHC 
implies that alternative services are being used. Information or 
resources on chemsex should be available via these avenues, for 
example, links on self- sampling/self- testing websites.
Chemsex services should be culturally competent5 and address 
patient needs and demographics, for instance that chemsex partic-
ipants are more likely to originate from outside the UK. SHCs in 
England have long been praised for convenient, anonymous, and 
non- judgmental care. Investments to adapt to changing needs of 
attendees are needed to ensure they stay this way.
Key messages
 ► One in 10 men who have sex with men recruited through 
community and clinical settings across England had engaged 
in chemsex in the past year.
 ► Chemsex participants were more likely to be HIV- positive, 
aged 30–44, born outside the UK and report higher risk 
sexual behaviours.
 ► Among app- recruited respondents reporting chemsex, 66% 
had attended a sexual health clinic and 81% had had an STI 
test in the past year.
 ► Results highlight the need and opportunity for chemsex- 
related services in sexual health clinics and referral pathways 
to drug treatment services.
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